CCEL (Cryo-Cell International) Total Stockholders Equity: $-17.76 Mil (As of May. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CCEL Cryo-Cell International Inc CCEL
60 GF Score
Price $3.60
GF Value $5.55
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Cryo-Cell International Total Stockholders Equity?

Cryo-Cell International CCEL +0.84% 60 Total Stockholders Equity is $-17.76 Mil as of May. 2026. GuruFocus rates CCEL with a GF Score™ of 60/100 and a GF Value™ of $5.55 (Possible Value Trap). The stock has 4 warning signs investors should review.

Cryo-Cell International's Total Stockholders Equity for the quarter that ended in May. 2026 was $-17.76 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Cryo-Cell International's Book Value per Share for the quarter that ended in May. 2026 was $-2.20. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Cryo-Cell International's Debt-to-Equity for the quarter that ended in May. 2026 was -0.50.

Cryo-Cell International  (AMEX:CCEL) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Cryo-Cell International's Book Value per Share for the quarter that ended in May. 2026 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(-17.758-0)/8.063
=-2.20

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Cryo-Cell International's Debt-to-Equity for the quarter that ended in May. 2026 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.617 + 8.343) / -17.758
=-0.50

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cryo-Cell International Total Stockholders Equity Related Terms

Cryo-Cell International Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Cryo-Cell International's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cryo-Cell International Total Stockholders Equity Chart

Cryo-Cell International Annual Data
Trend Nov16 Nov17 Nov18 Nov19 Nov20 Nov21 Nov22 Nov23 Nov24 Nov25
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.18 -1.52 -11.03 -13.22 -18.61

Cryo-Cell International Quarterly Data
Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26 May26
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -15.56 -14.83 -18.61 -18.40 -17.76
CCEL
60GF Score
Cryo-Cell International Inc CCEL
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of $-17.76 Mil mean?
Cryo-Cell International (CCEL) has a Total Stockholders Equity of $-17.76 Mil as of May. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Cryo-Cell International and its competitors.
Is Cryo-Cell International's Total Stockholders Equity too high?
Cryo-Cell International's current Total Stockholders Equity is $-17.76 Mil. Overall, Cryo-Cell International has a GF Score™ of 60/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cryo-Cell International's Total Stockholders Equity compare to EHSI and PIII?
Cryo-Cell International's Total Stockholders Equity of $-17.76 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Healthcare Providers & Services company?
A good Total Stockholders Equity depends on the Healthcare Providers & Services industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Cryo-Cell International and its competitors. Cryo-Cell International's current Total Stockholders Equity is $-17.76 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cryo-Cell International stock overvalued right now?
Based on GuruFocus' analysis, Cryo-Cell International (CCEL) is currently considered Possible Value Trap. The stock's GF Value™ is $5.55, compared to a current price of $3.60 — trading 35.1% below its estimated fair value. The current Total Stockholders Equity is $-17.76 Mil. Cryo-Cell International's overall GF Score™ is 60/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Cryo-Cell International (CCEL), the current Total Stockholders Equity is $-17.76 Mil as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cryo-Cell International (CCEL) Overvalued in 2026?

Based on GuruFocus' analysis, Cryo-Cell International stock appears to be undervalued. The current stock price of $3.60 is trading 35.1% below its estimated GF Value™ of $5.55. GuruFocus considers Cryo-Cell International to be Possible Value Trap.

Key valuation signals for CCEL:

  • Total Stockholders Equity: $-17.76 Mil
  • GF Value™: $5.55 vs. price of $3.60 (35.1% below fair value)
  • GF Score™: 60/100 with 4 warning signs

No single metric tells the full story. See the CCEL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cryo-Cell International Business Description

Other Exchanges ZCY:Germany
Address 700 Brooker Creek Boulevard, Suite 1800, Oldsmar, FL, USA, 34677
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.
60GF Score

Get the complete analysis for CCEL

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.60
Price
$5.55
GF Value